The index
Every compound on the shelf.
32 entries — structural biochemistry, primary literature, third-party COAs. No health claims. Every deep link takes 35% off, applied automatically.
NNMT (nicotinamide N-methyltransferase) inhibitor
5-Amino-1MQ
A small-molecule compound (5-amino-1-methylquinolinium iodide) — not a peptide, technically a substrate-mimetic inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Characterized in the 2010s primarily by Alessio Neri and Robert Messing's group and adjacent metabolic-disease labs.
Read the full note →
Human growth-hormone fragment (177–191)
AOD-9604
A synthetic peptide corresponding to the C-terminal 15-amino-acid fragment of human growth hormone (residues 177–191), with an added N-terminal tyrosine for stability. Originally developed by Metabolic Pharmaceuticals in the late 1990s as a putative fat-metabolism candidate lacking the growth-promoting activity of full-length hGH.
Read the full note →
Gastric pentadecapeptide
BPC-157
A synthetic 15-amino-acid peptide fragment corresponding to a sequence in Body Protection Compound (BPC), a protein produced in the stomach lining. First characterized by Predrag Sikirić's group at the University of Zagreb in the early 1990s.
Read the full note →
GHRH analog + GHRP
CJC-1295 / Ipamorelin (No DAC)
A blend of two peptides: CJC-1295 (a modified 30-residue GHRH analog with amino acid substitutions for enhanced stability) and Ipamorelin (a pentapeptide growth-hormone secretagogue receptor agonist). Sold in the 'No DAC' configuration — the drug affinity complex modification is omitted, shortening plasma half-life.
Read the full note →
Angiotensin IV analog (hexapeptide)
Dihexa
A hexapeptide (N-hexanoic-Tyr-Ile-(6) amino hexanoic amide) engineered as an orally-bioavailable analog of the angiotensin IV fragment 3-8. Developed by Joseph Harding and colleagues at Washington State University as a research tool for the hepatocyte growth factor / c-Met pathway in cognitive-decline models.
Read the full note →
Delta Sleep-Inducing Peptide (nonapeptide)
DSIP
A nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated by Marcel Monnier's group at the University of Basel in the mid-1970s, from cerebral venous blood of rabbits during electrically-induced delta-wave EEG sleep. Never developed as a pharmaceutical; remains a research-only compound.
Read the full note →
Synthetic tetrapeptide bioregulator
Epithalon
Alanyl-glutamyl-aspartyl-glycine (Ala-Glu-Asp-Gly) — a synthetic tetrapeptide developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, first published in the mid-1990s. Also spelled Epitalon.
Read the full note →
Copper tripeptide
GHK-Cu
A copper-binding tripeptide — glycyl-L-histidyl-L-lysine coordinated to a divalent copper ion. Isolated from human plasma by Loren Pickart, 1973.
Read the full note →
Three-peptide combination stack (BPC-157 + TB-500/TB-4 + GHK-Cu)
GLOW
A vendor-formulated combination of three research peptides — BPC-157 (a synthetic pentadecapeptide), TB-500 (a 17-residue fragment of thymosin β-4), and GHK-Cu (the copper-tripeptide glycyl-histidyl-lysine). Sold in a single lyophilized vial at roughly a 5-to-1-to-1 mass ratio favoring GHK-Cu (approximately 52 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-4 per 70 mg vial, per the vendor's lot COAs). Each constituent has its own literature record; the combination itself is a marketing construct, not a published research protocol.
Read the full note →
Endogenous tripeptide antioxidant
Glutathione
γ-L-glutamyl-L-cysteinyl-glycine — a tripeptide central to intracellular redox chemistry. Not a novel research compound: characterized biochemically since the late 1800s, structurally by Frederick Gowland Hopkins, 1921.
Read the full note →
Modified IGF-1 analog (Long R3 variant)
IGF-1 LR3
An 83-amino-acid analog of insulin-like growth factor 1 with an N-terminal 13-residue extension (from methionyl-porcine growth hormone) and a single Arg-for-Glu substitution at position 3. The Long R3 modification substantially reduces binding to circulating IGF-binding proteins, extending plasma half-life relative to native IGF-1.
Read the full note →
Selective GHSR agonist (GHRP)
Ipamorelin
A synthetic pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — that acts as a selective agonist of the growth-hormone secretagogue receptor (GHSR / ghrelin receptor). Discovered and characterized by Kirsten Raun and colleagues at Novo Nordisk in the mid-1990s.
Read the full note →
Hypothalamic GPR54 agonist
Kisspeptin
A family of peptides (Kisspeptin-54, -14, -13, -10) derived from the KISS1 gene product. Discovered as a metastasis-suppressor gene in 1996, later shown to encode the endogenous ligand of the GPR54/KISS1R receptor and the upstream master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Central hypothalamic role clarified in the early 2000s by de Roux and Seminara.
Read the full note →
Four-peptide combination stack (BPC-157 + TB-500 + GHK-Cu + KPV)
KLOW
A vendor-formulated combination of four research peptides — BPC-157 (a synthetic pentadecapeptide), TB-500 (a 17-residue fragment of thymosin β-4), GHK-Cu (the copper-tripeptide glycyl-histidyl-lysine), and KPV (the C-terminal α-MSH tripeptide lysine-proline-valine). Sold in a single lyophilized vial at approximately a 5-to-1-to-1-to-1 mass ratio favoring GHK-Cu (roughly 52 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV per 80 mg vial, per the vendor's lot COAs). Each constituent has its own literature record; the combination itself is a marketing construct — essentially GLOW with KPV added — not a published research protocol.
Read the full note →
α-MSH tripeptide fragment
KPV
Lysine-proline-valine — a synthetic tripeptide corresponding to the C-terminal three residues of α-melanocyte stimulating hormone (α-MSH). The parent α-MSH is a 13-residue neuropeptide characterized across decades of endocrine literature.
Read the full note →
Human cathelicidin peptide
LL-37
The 37-amino-acid mature peptide cleaved from human cathelicidin antimicrobial protein (hCAP-18), encoded by the CAMP gene. The only cathelicidin in humans. Broadly characterized since the 1990s for direct antimicrobial activity and, later, for immunomodulatory signaling through formyl-peptide receptor 2 (FPR2) and other receptors.
Read the full note →
Cyclic α-MSH analog (13-residue)
Melanotan I
A cyclic 13-amino-acid analog of α-melanocyte stimulating hormone (α-MSH), developed at the University of Arizona (Hadley, Hruby, Sawyer group) in the 1980s. Corresponds to the INN afamelanotide, which is FDA-approved for a single specific clinical indication (erythropoietic protoporphyria) under a branded prescription formulation held by Clinuvel Pharmaceuticals.
Read the full note →
Cyclic α-MSH analog
Melanotan II
A cyclic synthetic 7-amino-acid analog of α-melanocyte stimulating hormone (α-MSH). Originally developed at the University of Arizona (Hadley, Hruby group) in the 1980s. Not FDA-approved; distinct from Melanotan I (afamelanotide), which IS FDA-approved under its own branded formulation for erythropoietic protoporphyria.
Read the full note →
Mitochondrial-derived peptide
MOTS-c
A 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene — one of the first recognized 'mitochondrial-derived peptides.' Identified and characterized by Changhan Lee, Pinchas Cohen, and colleagues at USC, published 2015 in Cell Metabolism.
Read the full note →
Pyridine coenzyme
NAD+
Nicotinamide adenine dinucleotide — a coenzyme central to oxidation-reduction reactions in every living cell. Identified by Harden and Young, 1906; structural characterization completed by Warburg, 1936.
Read the full note →
Cyclic melanocortin agonist
PT-141
A cyclic 7-amino-acid peptide melanocortin-receptor agonist developed by Palatin Technologies from the α-MSH template. The compound corresponds to the INN bremelanotide, which is FDA-approved as a prescription drug for a single specific clinical indication.
Read the full note →
GIP + GLP-1 + glucagon triple agonist
Retatrutide
A synthetic 39-amino-acid peptide (also known as LY3437943) that binds three receptors: GIP, GLP-1, and glucagon. Investigational Eli Lilly compound; not FDA-approved as of writing.
Read the full note →
Synthetic tuftsin analog (heptapeptide)
Selank
A synthetic 7-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) — an analog of the immunomodulatory tetrapeptide tuftsin extended with proline-glycine-proline for stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside Semax. Approved as a prescription anxiolytic in the Russian Federation; not FDA-approved.
Read the full note →
GLP-1 receptor agonist
Semaglutide
A 31-residue analog of human GLP-1 (~94% sequence homology) with a C18 fatty-diacid chain attached via a linker — the modification drives reversible albumin binding and extended plasma half-life. The GLP-1 receptor agonist researchers reference by this name.
Read the full note →
Synthetic ACTH(4-10) analog with Pro-Gly-Pro tail
Semax
A synthetic 7-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) — an analog of the 4-10 fragment of ACTH extended at the C-terminus with a proline-glycine-proline sequence for peptidase resistance. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the late 1980s. Approved in the Russian Federation as a prescription drug; not FDA-approved.
Read the full note →
GHRH analog (29-residue N-terminal fragment)
Sermorelin
A synthetic peptide corresponding to the first 29 amino acids of human growth-hormone-releasing hormone (GHRH 1-29 NH₂) — the shortest N-terminal fragment retaining full biological activity at the GHRH receptor. Was previously FDA-approved as a prescription drug for pediatric growth-hormone deficiency; that branded formulation was commercially discontinued in the United States in 2008 (withdrawn from the market, not for safety reasons).
Read the full note →
Thymosin β-4 fragment
TB-500
A synthetic peptide corresponding to the acetylated N-terminal fragment of thymosin β-4 (TMSB4X), a 43-amino-acid actin-binding protein originally isolated from thymic tissue. Characterized by Allan Goldstein and colleagues at George Washington University, 1980s onward.
Read the full note →
GHRH analog
Tesamorlin
A synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH), stabilized by a trans-3-hexenoyl modification at the N-terminus. Developed by Theratechnologies. FDA-reviewed 2010 for a single specific clinical indication (published in the FDA label).
Read the full note →
Thymic 28-residue peptide (acetylated)
Thymosin Alpha-1
A 28-amino-acid N-acetylated peptide originally isolated from thymic tissue by Allan Goldstein and Abraham White in the mid-1970s at what became George Washington University. The compound corresponds to the INN thymalfasin, which is approved as a prescription drug in roughly 35 countries for hepatitis B, hepatitis C, and certain immunocompromised patient populations — but is NOT FDA-approved in the United States.
Read the full note →
GIP + GLP-1 dual agonist
Tirzepatide
A 39-residue synthetic linear peptide engineered as a dual receptor agonist at both the GIP receptor and the GLP-1 receptor. Developed by Eli Lilly; the dual incretin-receptor agonist researchers reference by this name.
Read the full note →
Vasoactive Intestinal Peptide (28 residues)
VIP
Vasoactive Intestinal Peptide — a 28-amino-acid signaling peptide in the secretin/glucagon superfamily. Isolated by Said and Mutt from porcine duodenum in 1970. Widely characterized as a neurotransmitter, neuromodulator, and immunomodulator across five decades of literature.
Read the full note →
Two-peptide combination stack (BPC-157 + TB-500/TB-4)
Wolverine Stack
A vendor-formulated combination of two research peptides — BPC-157 (a synthetic 15-amino-acid pentadecapeptide derived from a sequence in Body Protection Compound, a stomach-lining protein) and TB-500 (a 17-residue fragment of the endogenous protein thymosin β-4). Each constituent has its own decades-long literature record; the combination itself is a marketing construct, not a published research protocol. Sold in a single lyophilized vial at approximately a 1-to-1 mass ratio (5.32 mg BPC-157 + 5.11 mg TB-500 per 10 mg vial, per the vendor's lot COA).
Read the full note →
Method
Every entry begins with the structural record — IUPAC name where applicable, molecular class, discovery year, principal investigating groups. Literature portals link to author-scoped Google Scholar and PubMed searches. Every vendor claim is drawn from a lot-specific third-party COA. We do not sell, dispense, or prescribe. See the full method note.